Solana (NASDAQ:HSDT) versus iRadimed (NASDAQ:IRMD) Financial Review

iRadimed (NASDAQ:IRMD) and Solana (NASDAQ:HSDT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares iRadimed and Solana’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iRadimed	26.82%	23.83%	20.83%
Solana	-39,358.88%	-699.93%	-301.82%

Volatility & Risk

iRadimed has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Solana has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.

Insider & Institutional Ownership

92.3% of iRadimed shares are held by institutional investors. Comparatively, 18.6% of Solana shares are held by institutional investors. 36.8% of iRadimed shares are held by insiders. Comparatively, 17.2% of Solana shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for iRadimed and Solana, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0	1	3	0	2.75
Solana	1	0	0	0	1.00

iRadimed presently has a consensus target price of $120.00, suggesting a potential upside of 23.25%. Given iRadimed’s stronger consensus rating and higher possible upside, equities analysts clearly believe iRadimed is more favorable than Solana.

Valuation & Earnings

This table compares iRadimed and Solana”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81 million	14.85	$22.48 million	$1.75	55.63
Solana	$520,000.00	152.49	-$11.74 million	($1,267.04)	0.00

iRadimed has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Summary

iRadimed beats Solana on 13 of the 14 factors compared between the two stocks.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.